LifeVantage Corporation announced its financial results for the first quarter of fiscal 2027. Revenue during the period was $37.1 million, a 22% year-over-year decrease. Revenue in the Americas fell 22.2% to $29 million while revenue in the Asia/Pacific & Europe region fell 21.2% to $8.2 million. The company attributed this decline primarily to lower active accounts, reflecting impacts from the broader macro environment and lower sales of the MindBody GLP-1 System. These declines were partially offset, however, by sales of the LoveBiome product line, which LifeVantage acquired in October of 2025.
Gross profit during the quarter was $28 million, or 75.4% of revenue, down from $37.8 million and 79.5% of revenue in the previous year’s quarter. An allowance for inventory obsolescence related to the MindBody GLP-1 System was the primary contributor to this decline, as well as increased shipping and warehouse related expenses.
The company reported an operating loss for the quarter of $0.1 million compared to an operating income of $2.3 million in the same period of 2025. Net loss for the quarter was $0.2 million, or $0.02 per diluted share, with an adjusted EBITDA of $1.9 million, or 5.2% of revenue.
“Despite a challenging quarter, LifeVantage has significant untapped potential, and we now have a clear strategy designed to capture it,” said Terrence Moorehead, LifeVantage President and Chief Executive Officer. “Our focus is on transforming LifeVantage into a more brand-driven, consumer-focused company, supported by a modern digital platform and an expanding community of consumers and brand advocates. At the same time, we are creating a more focused and efficient operating model and strengthening the underlying economics of the business. We have a lot of work to do, and building the company we envision will take time, but we have a differentiated foundation, a clear roadmap and a strong sense of urgency around execution. The actions we are taking are designed to build a stronger, more relevant LifeVantage and create sustainable long-term value for our shareholders.”
LifeVantage generated $0.5 million in cash from operations during the three months ending September 30, 2026, compared to $2.3 million used in operations in the same period last year. The company ended the quarter with cash and cash equivalents of $13.7 million, compared to $14.9 million in the previous sequential quarter.
